Medical Department Virbac, 13ème Rue, 06511 Carros, France.
R&D Virbac, Carros, France.
Ir Vet J. 2014 May 19;67(1):10. doi: 10.1186/2046-0481-67-10. eCollection 2014.
Intestinal phosphate binders, uremic toxin binders and some other types of supplements are an integral part of the management of chronic kidney disease (CKD) in various species, including cats. This pathology in domestic carnivores requires life-long nutritional and medical management. In this context, the compliance of owners and patients cannot be achieved without an adequate level of palatability for oral medication or supplementation. Knowing that hyporexia and anorexia are among the most commonly seen clinical signs in cats suffering from CKD this is already, in itself, a serious obstacle to acceptable compliance in sick animals. The aim of the present study was to investigate the palatability of four commercially available products designed for cats suffering from CKD: Ipakitine® (Vetoquinol, France), Azodyl® (Vetoquinol, USA), Renalzin® (Bayer, France), Rubenal® (Vetoquinol, France) and an additional recently developed product: Pronefra® (Virbac, France). The study was performed with a group of previously-characterised cats, all living in an enriched and well-being securing environment of an independent centre housing panels of pets expert in palatability measurement. In total 172 monadic testings were performed. The palatability of each product was assessed by measuring their rates of prehension and consumption, and the consumption proportions were also analysed.
The most palatable presentation (based on useful consumption) was Pronefra®, which was significantly higher than Azodyl® (p = 0.046), Ipakitine® (p < 0.0001), Renalzin® (p < 0.0001) and Rubenal® (p < 0.0001). The product with the highest rate of prehension was also Pronefra®, which was significantly higher than Azodyl® (p = 0.0019), Ipakitine® (p = 0.0023), Renalzin® (p = 0.0008) and Rubenal® (p < 0.0001).
Pronefra® was the most palatable presentation tested, meaning it may be useful for improving ease of supplementation in CKD cats.
肠道磷酸盐结合剂、尿毒症毒素结合剂和其他一些类型的补充剂是各种物种（包括猫）慢性肾脏病（CKD）管理的重要组成部分。在这些家养食肉动物中，这种病理学需要终身的营养和医疗管理。在这种情况下，如果口服药物或补充剂的适口性得不到足够的保证，那么主人和患者就无法遵守。由于厌食和食欲不振是 CKD 猫最常见的临床症状之一，这本身就是导致患病动物难以接受的严重障碍。本研究的目的是调查四种专为 CKD 猫设计的市售产品的适口性：Ipakitine®（Vetoquinol，法国）、Azodyl®（Vetoquinol，美国）、Renalzin®（Bayer，法国）、Rubenal®（Vetoquinol，法国）和最近开发的一种产品：Pronefra®（Virbac，法国）。该研究是在一组已被确认的猫中进行的，这些猫都生活在一个独立的宠物中心，这里有丰富的环境和福祉保障，还有专门从事适口性测量的宠物小组。总共进行了 172 次单项测试。通过测量每种产品的摄取和消耗率来评估其适口性，并分析消耗比例。
根据有效消耗，最可口的产品是 Pronefra®，它显著高于 Azodyl®（p=0.046）、Ipakitine®（p<0.0001）、Renalzin®（p<0.0001）和 Rubenal®（p<0.0001）。摄食率最高的产品也是 Pronefra®，它显著高于 Azodyl®（p=0.0019）、Ipakitine®（p=0.0023）、Renalzin®（p=0.0008）和 Rubenal®（p<0.0001）。
Pronefra®是测试中最可口的产品，这意味着它可能有助于提高 CKD 猫的补充剂易用性。
